Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Financing Activities (2024 - 2025)

Silence Therapeutics' Cash from Financing Activities history spans 2 years, with the latest figure at $1000.0 for Q2 2025.

  • For Q2 2025, Cash from Financing Activities fell 99.92% year-over-year to $1000.0; the TTM value through Dec 2025 reached $15000.0, down 99.99%, while the annual FY2025 figure was $15000.0, 99.99% down from the prior year.
  • Cash from Financing Activities for Q2 2025 was $1000.0 at Silence Therapeutics, down from $14000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $133.0 million in Q1 2024 and bottomed at -$98000.0 in Q4 2024.